savolitinib,durvalumab
hutchmed,astrazeneca,orpathys
['savolitinib', 'calypso', 'durvalumab']
#asco22 presents data from calypso trial in clear cell #kidneycancer of savolitinib alone or with durvalumab did not meet the pre specified efficacy endpoint of 50% orr. #ascodailynews calypso continues in papillary mrcv 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E